| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 01/23/2003 | WO2002047731A3 Drug delivery compositions and coated medical devices |
| 01/23/2003 | WO2002045662A3 Anhydrous creams, lotions and gels |
| 01/23/2003 | WO2002043694A3 Edible pga(propylene glycol alginate) coating composition |
| 01/23/2003 | WO2002038133A3 Compositions containing hydrolytically unstable compounds |
| 01/23/2003 | WO2002036767A3 Therapeutic oligonucleotides of reduced toxicity |
| 01/23/2003 | WO2002026265A3 Pegylated interleukin-10 |
| 01/23/2003 | WO2002026208A3 Emulsion vehicle for poorly soluble drugs |
| 01/23/2003 | WO2002024157A3 Acryl adhesive useful in transdermal drug delivery systems |
| 01/23/2003 | WO2002016553A3 Regulator gene and system useful for the diagnosis and therapy of osteoporosis |
| 01/23/2003 | WO2002008293A3 Multivalent target binding protein |
| 01/23/2003 | US20030018371 Compositions and methods for the treatment of metabolic bone disorders and bone metastases |
| 01/23/2003 | US20030018222 Sovent extracting the dried marigold flower petals, eluting through an anion exchange resin column, diluting the eluent, crystallization; protecting lutein against deterioration, store for long time |
| 01/23/2003 | US20030018176 Dry acid-chitosan complexes |
| 01/23/2003 | US20030018085 Isostearic acid salts as permeation enhancers |
| 01/23/2003 | US20030018083 Methods of treating and preventing pain, anxiety, and incontinence using derivatives of (-)-venlafaxine |
| 01/23/2003 | US20030018072 Utilization of dialkylfumarates |
| 01/23/2003 | US20030018011 Fatty acid-containing composition |
| 01/23/2003 | US20030018002 Gene therapy |
| 01/23/2003 | US20030017979 Antibody and chemokine constructs and their use in the treatment of infections and immunological diseases |
| 01/23/2003 | US20030017972 Drug delivery |
| 01/23/2003 | US20030017964 Administration of agents via the PEPT-2 transporter |
| 01/23/2003 | US20030017617 Mammalian receptor proteins; related reagents and methods |
| 01/23/2003 | US20030017456 Diagnosis and treatment and related preparations |
| 01/23/2003 | US20030017210 Controlled-release for oral administration of cisplatin |
| 01/23/2003 | US20030017207 Compositions and methods for treating vulvovaginitis and vaginosis |
| 01/23/2003 | US20030017206 Negatively charged amphiphilic block copolymer as drug carrier |
| 01/23/2003 | US20030017204 Microcrystalline cellulose and carrageenan and a strengthening polymer and/or a plasticizer |
| 01/23/2003 | US20030017203 Lamination with a first layer of a pH-lowering agent and a second layer of a peptide, an absorption enhancer to promote bioavailability and enteric coating |
| 01/23/2003 | US20030017201 Pharmaceutical composition comprising entracapone, levodopa, and carbidopa |
| 01/23/2003 | US20030017200 Oral administration of terbinafine, a buffering component and a disintegrant; fungicides |
| 01/23/2003 | US20030017199 Compositions having enhanced pharmacokinetic characteristics |
| 01/23/2003 | US20030017197 Pharmaceutical and diagnostic compositions containing nanoparticles useful for treating targeted tissues and cells |
| 01/23/2003 | US20030017196 Oligonucleotide inhibitors of bcl-xL |
| 01/23/2003 | US20030017181 Including one or more anesthetic agents and/or one or more anti-inflammatory agents and/or a combination of ammonium, sodium, and potassium salts, preferably of an alpha-hydroxy acid |
| 01/23/2003 | US20030017176 Preparations of the W/O emulsion type with an increased water content, comprising moderately polar lipids and silicone emulsifiers and, if desired, cationic polymers |
| 01/23/2003 | US20030017169 Controlled release systems for polymers |
| 01/23/2003 | US20030017164 Dye-azide compounds for dual phototherapy |
| 01/23/2003 | US20030017140 Retroviral vector particles have a chimeric envelope protein consisting of an antigen binding site of an antibody or another peptide, fused to the envelope protein the retroviral vector. |
| 01/23/2003 | US20030017133 Composition comprising a medicament and a film forming vehicle comprising polymethacrylate, and an adhesive that sticks to mucous membranes. |
| 01/23/2003 | US20030017130 A hydroxycarboxylic acid is present in the form of a free acid, lactone, or salt and a retinoid in stereoisomeric or non-isomeric form |
| 01/23/2003 | US20030017120 Delivery of erectile dysfunction drugs through an inhalation route |
| 01/23/2003 | US20030017119 Aerosol comprises particles comprising at least 10 percent by weight of an opioid, and wherein the opioid is not heroin; opiods include morphine, codeine, naltrexone, buprenorphine, fentanyl, nalbuphine, naloxone, etc. |
| 01/23/2003 | US20030017118 An aerosol for inhalation therapy, wherein the aerosol comprises particles comprising at least 10 percent by weight of an antipsychotic such as olanzapine, trifluoperazine, haloperidol, loxapine, clozapine, quetiapine, promazine, etc. |
| 01/23/2003 | US20030017117 Delivery of analgesics through an inhalation route |
| 01/23/2003 | US20030017116 Delivery of sedative-hypnotics through an inhalation route |
| 01/23/2003 | US20030017115 Aerosol comprises particles comprising at least 10 percent by weight of a drug ester. |
| 01/23/2003 | US20030017114 Aerosol comprises particles of chlordiazepoxide, betahistine, clonidine, testosterone, conjugated estrogens, estrogen esters, estradiol, estradiol esters, ethinyl estradiol, ethinyl estradiol esters, or hyoscyamine. |
| 01/23/2003 | US20030017113 Spray dried particles having specified aerodynamic characteristics are produced by atomizing a liquid feed and contacting the liquid feed with a drying gas, such as, for example, air or nitrogen. |
| 01/23/2003 | US20030017109 Mixable combination for generating a suspension of stable microbubbles for ultrasonic imaging |
| 01/23/2003 | US20030015190 Delivery of compounds for the treatment of migraine through an inhalation route |
| 01/23/2003 | US20030015189 Delivery of antihistamines through an inhalation route |
| 01/23/2003 | CA2454106A1 Mixed complexes for masking the taste of bitter active substances |
| 01/23/2003 | CA2453784A1 A core formulation |
| 01/23/2003 | CA2453782A1 Core formulation comprising troglitazone and a biguanide |
| 01/23/2003 | CA2453775A1 Core formulation comprising pioglitazone hydrochloride and a biguanide |
| 01/23/2003 | CA2453557A1 Keratin-based products and methods for their productions |
| 01/23/2003 | CA2453389A1 Aerosol formulations of .delta.8 tetrahydrocannabinol |
| 01/23/2003 | CA2453384A1 Insert for the treatment of dry eye |
| 01/23/2003 | CA2453216A1 Amphiphilic star-like macromolecules for drug delivery |
| 01/23/2003 | CA2453179A1 N,n-dinitramide salts as solubilizing agents for biologically active agents |
| 01/23/2003 | CA2453111A1 Pharmaceutical formulation for the intramuscular administration of fulvestrant |
| 01/23/2003 | CA2452582A1 G-csf conjugates |
| 01/23/2003 | CA2452382A1 Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres |
| 01/23/2003 | CA2451776A1 Enhancement of the stability of oligonucleotides comprising phosphorothioate linkages by addition of water-soluble antioxidants |
| 01/23/2003 | CA2451469A1 Use of antimicrobial peptides as preservatives in ophthalmic preparations including solutions emulsions and suspensions |
| 01/23/2003 | CA2448814A1 Composition for sustained release injections and production method thereof |
| 01/23/2003 | CA2448558A1 Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery |
| 01/22/2003 | EP1277838A1 Recombinant anti-tumor RNASE |
| 01/22/2003 | EP1277787A1 Method for preparing microsphere |
| 01/22/2003 | EP1277479A2 Alkali or alkaline earth metal benzoate particles |
| 01/22/2003 | EP1277471A1 Stable liquid preparation |
| 01/22/2003 | EP1277470A1 Injectable galenical formulation for use in photodynamic diagnostic or therapy and process of manufacturing it |
| 01/22/2003 | EP1277467A2 Non-chlorofluorocarbon aerosol formulations |
| 01/22/2003 | EP1277466A1 Patch containing anti-inflammatory agent |
| 01/22/2003 | EP1277465A1 Process for producing microsphere |
| 01/22/2003 | EP1277464A2 Liposome coated with polyhydroxyalkanoate and production method thereof |
| 01/22/2003 | EP1276877A2 Agent for postoperative use after the removal of bone tumours |
| 01/22/2003 | EP1276856A1 Albumin fusion proteins |
| 01/22/2003 | EP1276849A2 Albumin fusion proteins |
| 01/22/2003 | EP1276759A2 Reductive alkylation process on glycopeptides |
| 01/22/2003 | EP1276747A1 The use of azalide antibiotic compositions for treating or preventing a bacterial or protozoal infection in mammals |
| 01/22/2003 | EP1276672A2 Improved method and apparatus for generating an aerosol |
| 01/22/2003 | EP1276510A1 Coloured ophthalmic product |
| 01/22/2003 | EP1276508A2 A particulate complex for administering nucleic acid into a cell |
| 01/22/2003 | EP1276507A2 High affinity peptide-containing nanoparticles |
| 01/22/2003 | EP1276506A2 Sustained release drug compositions |
| 01/22/2003 | EP1276505A1 Mixtures of triblock polyesterpolyethylene glycol copolymers |
| 01/22/2003 | EP1276495A1 Novel use of pulmonary surfactant for the prophylaxis or early treatment of acute pulmonary diseases |
| 01/22/2003 | EP1276486A2 Joint repair using mesenchymal stem cells |
| 01/22/2003 | EP1276485A2 Compositions useful in the treatment of diseases of connective tissues comprising a ferrous ion and an ascorbate |
| 01/22/2003 | EP1276475A2 Topical anesthetic/opioid formulations and uses thereof |
| 01/22/2003 | EP1276474A2 Formulations for use in inhaler devices |
| 01/22/2003 | EP1276473A2 Pharmaceutical formulations for dry powder inhalers |
| 01/22/2003 | EP1276472A2 Formulations for use in inhaler devices |
| 01/22/2003 | EP1276471A2 Membrane delivery system |
| 01/22/2003 | EP1276469A2 Taste masking coating composition |
| 01/22/2003 | EP1276468A1 Use of particulate vectors in immunomodulation |
| 01/22/2003 | EP1276467A2 Guaifenesin sustained release formulation and tablets |
| 01/22/2003 | EP1276466A2 Directly compressed solid dosage particles |
| 01/22/2003 | EP1276465A2 Improved water-insoluble drug particle process |